Latest news with #Abelacimab
Yahoo
04-04-2025
- Business
- Yahoo
Blackstone Life Sciences and Anthos Therapeutics Announce Novartis has Completed the Acquisition of Anthos Therapeutics in a Deal Valued at up to $3.1B, with $925M Paid Upfront
The deal affirms Blackstone's vision of building companies around innovative products to meet unmet patient needs CAMBRIDGE, Mass., April 03, 2025--(BUSINESS WIRE)--Blackstone Life Sciences and Anthos Therapeutics, Inc., a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of cardiometabolic diseases, announced today that Novartis has completed its acquisition of Anthos Therapeutics in a transaction valued at up to $3.1 billion. Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel Factor XI inhibitor that originated at Novartis. Abelacimab is currently in Phase 3 clinical development for the prevention of stroke and systemic embolism in patients with atrial fibrillation (LILAC-TIMI 76), in addition to two phase 3 studies in patients with cancer-associated thrombosis (ASTER and MAGNOLIA). Data from these trials are expected in the second half of 2026. Transaction Details Anthos shareholders will receive up to $3.1 billion in total deal value, including an upfront payment of $925 million, and payments in the event certain regulatory and commercial milestones are achieved. Advisors Goldman Sachs & Co. LLC acted as the lead financial advisor to Anthos. Morgan Stanley & Co. LLC also served as a financial advisor, and Goodwin Procter LLP served as legal advisor to Anthos. About Blackstone Life Sciences Blackstone Life Sciences (BXLS) is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science sectors. By combining scale investments and hands-on operational leadership, BXLS helps bring to market promising new medicines and medical technologies that improve patients' lives and currently has $12 billion in assets under management. About Anthos Therapeutics Founded by BXLS in 2019, Anthos Therapeutics is a transformative, clinical-stage biopharmaceutical company with exclusive global rights from Novartis Pharma AG to develop, manufacture and commercialize abelacimab. BXLS was the majority investor in the company, joined by other partners including Novo Holdings. For more information about Anthos, visit the Company's website. About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the activated form (Factor XIa). This mimics natural Factor XI deficiency, which is associated with protection from thromboembolic disease. Abelacimab received a Fast Track Designation from the FDA in July 2022 for the treatment of thrombosis associated with cancer. In September 2022, abelacimab was also granted a Fast Track Designation for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the expected benefits of Novartis' acquisition of Anthos, future opportunities for the combined businesses, the development and commercialization of Anthos Therapeutics' product candidates and the potential benefits of abelacimab. All statements, other than statements of historical facts, contained in this press release, including statements regarding the company's strategy, future operations, future financial position, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "become," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. Actual results may differ materially because of numerous risks and uncertainties including with respect to (i) the risk that the expected benefits or synergies of the acquisition will not be realized and (ii) the risk that the milestones may not be achieved and resulting payments may not be realized, and (iii) unanticipated impact of the acquisition, including the response of business partners and competitors to the announcement of the acquisition or difficulties in employee retention. The actual financial impact of this transaction may differ from the expected financial impact described in this press release. In addition, the product candidate described in this press release is subject to all the risks inherent in the drug development process, and there can be no assurance that its development will be commercially successful. No forward-looking statement can be guaranteed. In addition, the forward-looking statements included in this press release represent the company's views as of the date hereof and should not be relied upon as representing the company's views as of any date subsequent to the date hereof. The company anticipates that subsequent events and developments will cause the company's views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so. View source version on Contacts Media Blackstone Paula Sign in to access your portfolio
Yahoo
11-02-2025
- Business
- Yahoo
Novartis signs agreement to acquire Anthos for $925m upfront
Novartis has agreed to acquire Boston-based clinical-stage biopharmaceutical company Anthos Therapeutics for an upfront payment of $925m. The transaction includes $2.15bn of potential additional payments, contingent on regulatory and sales milestones. It is anticipated to close in the first half of 2025. The acquisition aligns with Novartis' growth strategy and therapeutic area focus, capitalising on the company's established strengths in the cardiovascular domain. Novartis Development president and chief medical officer Shreeram Aradhye stated: 'We are excited to join forces to advance the development of abelacimab, a potential first-in-class treatment and safer approach for stroke prevention in atrial fibrillation as well as cancer-associated thrombosis. 'Welcoming Anthos Therapeutics strengthens our focus in the cardiovascular space and complements our portfolio of life-changing treatments, comprehensive clinical programmes and strategic collaborations that help thousands of patients with heart disease around the world.' Launched in 2019 by Novartis and Blackstone Life Sciences, Anthos has been developing abelacimab, a highly selective and fully human monoclonal antibody. Licenced from Novartis, the therapy targets Factor XI to achieve anticoagulation without compromising haemostasis. Phase II trials have demonstrated a significant decrease in bleeding events in subjects with atrial fibrillation treated with the antibody against those receiving standard direct-oral anticoagulants. Three Phase III trials are currently underway, investigating abelacimab for arterial and venous clots across various subject groups. The US Food and Drug Administration granted fast track status to the antibody in July 2022 for the treatment of thrombosis associated with cancer. In September 2022, it received fast track designation for the prevention of stroke and systemic embolism in atrial fibrillation patients. Abelacimab's mechanism of action involves binding to Factor XI and blocking its activation, thereby preventing the formation of Factor XIa. This approach is inspired by the natural deficiency of Factor XI, which is known to protect against thromboembolic conditions. "Novartis signs agreement to acquire Anthos for $925m upfront" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
11-02-2025
- Business
- Yahoo
Novartis to buy Anthos Therapeutics in $3.1 bn deal
Swiss pharmaceutical firm Novartis said on Tuesday that it has agreed to buy privately held, clinical-stage US biotech Anthos Therapeutics for up to $3.1 billion. As part of the agreed terms, Novartis will make an upfront payment of $925 million upon closing of the transaction, in addition to payments that depend on meeting specific regulatory and sales targets, totalling up to $2.15 billion. The deal is expected to be completed in the first half of 2025. Anthos Therapeutics, founded in 2019 by Blackstone Life Sciences and Novartis, specializes in developing treatments for cardiovascular diseases. As part of its launch, Anthos obtained the rights to develop and commercialize abelacimab, a drug aimed at preventing blood clots. With this acquisition, Novartis is bringing abelacimab back into its pipeline. Abelacimab is currently undergoing a third phase of clinical trials. Results from these studies are expected in the second half of 2026. The results from these studies are expected in the second half of 2026. Sign in to access your portfolio
Zawya
11-02-2025
- Business
- Zawya
Novartis buys Blackstone's Anthos for up to $3.1bln
Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's drug development unit, for up to $3.1 billion, to boost its cardiovascular business. Anthos was founded by private equity firm Blackstone's Life Sciences business and by Novartis in 2019 to develop, manufacture, and commercialise abelacimab, a treatment to prevent strokes and the recurrence of blood clots. The deal underlines the Swiss group's commitment to cardiovascular therapies, one of five medical areas that it is focusing on, as its best-selling heart failure drug Entresto loses patent protection this year. The transaction, expected to close in the first half of this year, also concludes a high-profile development partnership between a drug major and a private equity firm, an emerging funding model that has been explored by the industry. Novartis will pay $925 million upfront with additional payments of up to $2.15 billion, contingent on development achievements, the companies said in statements. A Blackstone spokesperson said the deal was the largest sale to date of a majority-owned Blackstone Life Sciences company. Reuters reported in December 2023 that Blackstone was exploring the sale of Anthos. Abelacimab belongs to a novel class of drugs known as factor XI inhibitors, designed to replace established blood thinners Eliquis by Bristol Myers-Squibb and Pfizer as well as Xarelto by Johnson & Johnson and Bayer , which are billion dollar sellers. Bristol-Myers Squibb, together with Johnson & Johnson, are working in late stages of clinical testing on drug candidate milvexian. Merck & Co is also in the factor XI race with a mid-stage development candidate. Germany's Bayer in 2023 suffered a huge setback in its effort to advance its factor XI drug. Nicholas Galakatos, chairman of Anthos' board of directors and global head of Blackstone Life Sciences, said the firm was proud to have launched and helped grow Anthos. "We believe abelacimab has the potential to be a leader in the new class of Factor XI anticoagulants and are pleased to have Novartis as a committed partner to advance the development and commercialization of abelacimab as a potential treatment ... for the millions of patients at risk of strokes," he said. Anthos is conducting several phase 3 clinical studies, with data from these trials expected in the second half of 2026, Blackstone said. Novartis said it already holds a small minority equity interest in Anthos, but declined to detail the size of it. (Reporting by Ludwig Burger, Ariane Luthi and Paolo Laudani Additional reporting by Paul Arnold Editing by Friederike Heine, Barbara Lewis and Kim Coghill)
Yahoo
11-02-2025
- Business
- Yahoo
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion
Reflects the promise of the novel Factor XI inhibitor class of medicines to help prevent strokes and other conditions as well as Abelacimab's potential to provide superior safety Culminates growth journey as part of Blackstone Life Sciences CAMBRIDGE, Mass., February 11, 2025--(BUSINESS WIRE)--Blackstone Life Sciences and Anthos Therapeutics, Inc. ("Anthos" or the "company"), a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of cardiometabolic diseases, announced today that the company has entered into an agreement with Novartis to acquire Anthos for up to $3.1 billion. Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel factor XI inhibitor that originated at Novartis, being developed to prevent stroke and systemic embolism in patients with atrial fibrillation as well as to prevent the recurrence of blood clots in patients with cancer. "Abelacimab has the potential to be an important treatment option for the millions of patients globally with atrial fibrillation at high risk of stroke, and we could not have more conviction in the potential of this asset," said Bill Meury, Chief Executive Officer at Anthos. "With its deep roots in the cardiovascular space, Novartis is especially well positioned to advance abelacimab's clinical development and bring this innovative product to healthcare providers and patients. I am deeply grateful to the Anthos and Blackstone Life Sciences teams, the clinical investigators, the patients in our studies, the advocacy community, and many others who have played a role in Anthos' success over the past six years." "We are proud to have launched and helped grow Anthos by acquiring the rights to abelacimab, assembling a world class team, designing the clinical plan and financing its development," said Dr. Nicholas Galakatos, Chairman of Anthos' Board of Directors and Global Head of Blackstone Life Sciences. "We believe abelacimab has the potential to be a leader in the new class of Factor XI anticoagulants and are pleased to have Novartis as a committed partner to advance the development and commercialization of abelacimab as a potential treatment option for the millions of patients at risk of strokes. This transaction is an affirmation of Blackstone Life Sciences' ownership investment strategy, where we seek to find innovative products and build companies around them to meet unmet patient needs." In AZALEA-TIMI 71, abelacimab compared with rivaroxaban (Xarelto) demonstrated a 62% reduction in major bleeding or clinically relevant non-major bleeding, a 67% reduction in major bleeding, and an 89% reduction in gastrointestinal bleeding. The overall clinical benefit of abelacimab prompted the Independent Data Monitoring Committee to discontinue the study early. Results from AZALEA-TIMI 71 were recently published in the New England Journal of Medicine on January 23, 2025. Anthos is currently conducting a phase 3 clinical study in patients with atrial fibrillation with high risk for stroke or systemic embolism (LILAC-TIMI 76) as well as two phase 3 studies in patients with cancer-associated thrombosis (ASTER and MAGNOLIA). Data from these trials are expected in the second half of 2026. Blackstone Life Sciences' investment in and commitment to Anthos demonstrate the power of combining its scale and deep operating expertise to build businesses that can help bring innovative products to market and substantially improve patient outcomes. Transaction Details Anthos shareholders will receive an upfront payment of $925 million upon closing of the transaction. In addition, Anthos shareholders are entitled to receive payments in the event certain regulatory and commercial milestones are achieved. Completion of the transaction is expected in the first half of 2025, pending the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and satisfaction of other customary closing conditions. Advisors Goldman Sachs & Co. LLC is acting as the lead financial advisor to Anthos. Morgan Stanley & Co. LLC is also serving as a financial advisor, and Goodwin Procter LLP is serving as legal advisor to Anthos. About Anthos Therapeutics Founded by Blackstone Life Sciences (BXLS) in 2019, Anthos Therapeutics is a transformative, clinical-stage biopharmaceutical company with the exclusive global rights from Novartis Pharma AG to develop, manufacture and commercialize abelacimab. BXLS is the majority investor in the company and is joined by other partners including Novo Holdings. For more information about Anthos, visit the Company's website or follow us on X and LinkedIn. About Blackstone Life Sciences Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science sectors. By combining scale investments and hands-on operational leadership, Blackstone Life Sciences helps bring to market promising new medicines and medical technologies that improve patients' lives and currently has $12 billion in assets under management. About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the activated form (Factor XIa). This mimics natural Factor XI deficiency, which is associated with protection from thromboembolic disease. Abelacimab received a Fast Track Designation from the FDA in July 2022 for the treatment of thrombosis associated with cancer. In September 2022, abelacimab was also granted a Fast Track Designation for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the proposed acquisition of Anthos by Novartis, the expected timetable for completing the transaction, future opportunities for the combined businesses, the expected benefits of Novartis' acquisition of Anthos, the development and commercialization of Anthos Therapeutics' product candidates and the potential benefits of abelacimab. All statements, other than statements of historical facts, contained in this press release, including statements regarding the company's strategy, future operations, future financial position, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "become," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. Actual results may differ materially because of numerous risks and uncertainties including with respect to (i) the possibility that various conditions to the consummation of the acquisition may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the acquisition, (ii) the risk that the expected benefits or synergies of the acquisition will not be realized, (iii) the risk that the milestones may not be achieved and resulting payments may not be realized, and (iv) unanticipated difficulties or expenditures relating to the proposed acquisition, including the response of business partners and competitors to the announcement of the proposed acquisition or difficulties in employee retention as a result of the announcement and pendency of the proposed acquisition. The actual financial impact of this transaction may differ from the expected financial impact described in this press release. In addition, the compounds described in this press release are subject to all the risks inherent in the drug development process, and there can be no assurance that the development of these compounds will be commercially successful. No forward-looking statement can be guaranteed. In addition, the forward-looking statements included in this press release represent the company's views as of the date hereof and should not be relied upon as representing the company's views as of any date subsequent to the date hereof. The company anticipates that subsequent events and developments will cause the company's views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so. View source version on Contacts Blackstone Paula Chirhart: Anthos Media contact: media@ Sign in to access your portfolio
